By Giulia Petroni 
 

Merck KGaA (MRK.XE) said Thursday that it has signed a license agreement to provide Promega Corporation with its Crispr intellectual property.

The Germany pharmaceuticals and chemicals company said Promega will use its technology to create research products and services, including those for drug development.

"Promega plans to use our intellectual property to develop Crispr-edited cell lines, which can play a major role in determining drug efficacy, toxicity and overall development," said Udit Batra, executive board member and chief executive of the Life Science business.

 

Write to Giulia Petroni at giulia.petroni@wsj.com

 

(END) Dow Jones Newswires

December 19, 2019 08:32 ET (13:32 GMT)

Copyright (c) 2019 Dow Jones & Company, Inc.
Merck KGaA (PK) (USOTC:MKKGY)
Historical Stock Chart
From Oct 2020 to Nov 2020 Click Here for more Merck KGaA (PK) Charts.
Merck KGaA (PK) (USOTC:MKKGY)
Historical Stock Chart
From Nov 2019 to Nov 2020 Click Here for more Merck KGaA (PK) Charts.